☆ 4.6 Letter

The Selective Use of Combination Therapy in Patients with Inflammatory Bowel Disease Resistant to Anti-TNF: to Whom, How and How Long?

JOURNAL OF CROHNS & COLITIS (2016)

Journal

JOURNAL OF CROHNS & COLITIS

Volume 10, Issue 12, Pages 1451-1451

Publisher

OXFORD UNIV PRESS

DOI: 10.1093/ecco-jcc/jjw089

Keywords

Anti-TNF; immunomodulator; combination therapy; Crohn's disease

Categories

Gastroenterology & Hepatology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Immunology

Effect of Anti-TNF Therapy on Mucosal Apoptosis Genes Expression in Crohn's Disease

Liliana Lykowska-Szuber, Michal Walczak, Marzena Skrzypczak-Zielinska, Joanna Suszynska-Zajczyk, Kamila Stawczyk-Eder, Katarzyna Waszak, Piotr Eder, Anna Wozniak, Iwona Krela-Kazmierczak, Ryszard Slomski, Agnieszka Dobrowolska

Summary: Crohn's disease patients who do not respond to anti-TNF therapy may have alterations in the expression levels of specific genes, particularly TNFRSF1B, FCGR3A, and IL1B. This can be predicted by functional analysis in colon biopsies and cell culture models.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Immunology

Characterization of Two TNF-Related Subtypes Predicting Infliximab Therapy Responses in Crohn's Disease

Chenglin Ye, Sizhe Zhu, Jingping Yuan

Summary: This study analyzed the gene expression profiles of patients with Crohn's disease (CD) and identified two gene subtypes: immune and metabolic. The immune subtype was associated with leukocyte migration and cytokine interactions, while the metabolic subtype was associated with metabolic pathways. The combination of interleukin 1 beta, interleukin 6, and Toll-like receptor 4 effectively distinguished between these two gene subtypes.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Immunomodulator comedication promotes the reversal of anti-drug antibody-mediated loss of response to anti-TNF therapy in inflammatory bowel disease

Johannes Stallhofer, Jan Guse, Miriam Kesselmeier, Philip Christian Grunert, Kathleen Lange, Robert Stalmann, Verena Eckardt, Andreas Stallmach

Summary: This study aimed to investigate the effects of immunomodulator comedication on anti-drug antibodies in patients with inflammatory bowel disease. The results of a real-world retrospective cohort study showed that immunomodulator comedication can successfully reverse the loss of therapeutic response to tumor necrosis factor inhibitors.

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Development of a Prediction Model for Short-Term Remission of Patients with Crohn's Disease Treated with Anti-TNF Drugs

Rosario Medina-Medina, Eva Iglesias-Flores, Jose M. Benitez, Sandra Marin-Pedrosa, Isabel Salgueiro-Rodriguez, Clara I. Linares, Sandra Gonzalez-Rubio, Pilar Soto-Escribano, Beatriz Gros, Manuel L. Rodriguez-Peralvarez, Jose L. Cabriada, Maria Chaparro, Javier P. Gisbert, Eduardo Chicano-Galvez, Ignacio Ortea, Gustavo Ferrin, Valle Garcia-Sanchez, Patricia Aguilar-Melero

Summary: Therapy with anti-TNF has transformed the treatment of Crohn's disease, but long-term efficacy is limited and adverse events can occur. This study aimed to find reliable markers to predict response to anti-TNF drugs in Crohn's disease patients. By comparing protein expression profiles in plasma samples, we identified 18 differentially expressed proteins, including vinculin, that may serve as biomarkers for short-term remission. Plasma vinculin levels, along with other factors such as baseline CD Activity Index, corticosteroid induction, and bowel resection, can predict non-short-term remission.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Genetics & Heredity

Landscape of sialylation patterns identify biomarkers for diagnosis and prediction of response to anti-TNF therapy in crohn's disease

Chenglin Ye, Sizhe Zhu, Yuan Gao, Yabing Huang

Summary: This study identified potential biomarkers for diagnosing Crohn's disease (CD) and predicting anti-TNF medication outcomes. The combined model of SERPINB2, TFPI2, and SLC9B2 showed excellent diagnostic value and the Sial-score had an outstanding ability to predict and distinguish between responders and non-responders. These findings have important implications for understanding the pathogenesis of CD and personalizing treatment for individual patients.

FRONTIERS IN GENETICS (2022)

Add to Collection

Article Gastroenterology & Hepatology

Association of Anti-TNF Therapy With Increased Risk of Acute Cholangitis in Patients With Primary Sclerosing Cholangitis

Chiraag Kulkarni, Soumya Murag, George Cholankeril, Touran Fardeen, Ajitha Mannalithara, Robert Lerrigo, Ahmad Kamal, Aijaz Ahmed, Aparna Goel, Sidhartha R. Sinha

Summary: This study found that anti-tumor necrosis factor (TNF) therapy was associated with increased odds of acute cholangitis, while immunomodulator use was protective. Anti-TNF therapy was associated with decreased time-to-cholangitis, with only 11.1% of patients who were prescribed immunomodulators developing cholangitis over the same time period.

INFLAMMATORY BOWEL DISEASES (2021)

Add to Collection

Article Gastroenterology & Hepatology

Anti-TNFα treatment in Crohn's disease: Impact on hepatic steatosis, gut-derived hormones and metabolic status

Paul Manka, Svenja Sydor, Nishikant Wase, Jan Best, Malte Brandenburg, Annika Hellbeck, Julia Schanzer, Ramiro Vilchez-Vargas, Alexander Link, Anja Figge, Andreas Jahnert, Ulrike von Arnim, Jason D. Coombes, Francisco-Javier Cubero, Alisan Kahraman, Moon-Sung Kim, Julia Kalsch, Sonja Kinner, Klaas-Nico Faber, Han Moshage, Guido Gerken, Wing-Kin Syn, Scott L. Friedman, Ali Canbay, Lars P. Bechmann

Summary: In this study, the potential relationship between anti-TNF treatment and hepatic steatosis in Crohn's disease was analyzed. Patients on anti-TNF treatment showed reduced hepatic steatosis, higher serum FGF19 levels, and lower levels of neutral lipids such as triglycerides. The abundance of Firmicutes, bacteria involved in bile acid metabolism and FGF19 regulation, was associated with triglyceride levels and showed group-specific alterations.

LIVER INTERNATIONAL (2021)

Add to Collection

Review Gastroenterology & Hepatology

Systematic review: efficacy of escalated maintenance anti-tumour necrosis factor therapy in Crohn's disease

Vandita Y. Mattoo, Chamara Basnayake, William R. Connell, Nik Ding, Michael A. Kamm, Mark Lust, Ola Niewiadomski, Alexander Thompson, Emily K. Wright

Summary: Empirical escalation of maintenance anti-TNF therapy can regain clinical response in a majority of patients with secondary loss of response to standard maintenance doses. Proactive optimization of maintenance dosing might prolong time to loss of response in some patients. Different strategies, such as dose intensification and early treatment escalation targeting biomarker normalisation, have shown associations with improved long-term outcomes.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)

Add to Collection

Article Gastroenterology & Hepatology

Earlier Anti-TNF Initiation Leads to Long-term Lower Health Care Utilization in Crohn's Disease but Not in Ulcerative Colitis

Laura E. Targownik, Charles N. Bernstein, Eric Benchimol, Gilaad G. Kaplan, Harminder Singh, Aruni Tennakoon, Zoann Nugent, Stephanie B. Coward, M. Ellen Kuenzig, Sanjay K. Murthy

Summary: Early administration of anti-TNF therapy is associated with reduced healthcare resource utilization in CD, but not in UC.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

Add to Collection

Article Nutrition & Dietetics

Earlier anti-TNF therapy reduces the risk of malnutrition associated with alterations in body composition in patients with Crohn's disease

Yuexin Wang, Danhua Yao, Yining He, Qi He, Yousheng Li

Summary: This study found that anti-TNF therapy can have an impact on the nutritional status of patients with Crohn's disease and even reverse malnutrition. Early application of anti-TNF therapy significantly affected the body composition of the patients, supporting their long-term nutritional status and reducing the probability of malnutrition.

FRONTIERS IN NUTRITION (2023)

Add to Collection

Article Genetics & Heredity

Pharmacogenetic Analysis of the MIR146A rs2910164 and MIR155 rs767649 Polymorphisms and Response to Anti-TNF Treatment in Patients with Crohn's Disease and Psoriasis

Paraskevi Nani, Melpomeni Ladopoulou, Evgenia H. Papaioannou, Evangelia D. Papagianni, Charalabos Antonatos, Panagiotis Xiropotamos, Andreas Kapsoritakis, Petros S. Potamianos, Konstantinos Karmiris, Charalambos Tzathas, Aikaterini Patsatsi, Elisavet Lazaridou, Efterpi Zafiriou, Angeliki Roussaki-Schulze, Sophia Georgiou, Katerina Grafanaki, Georgios K. Georgakilas, Yiannis Vasilopoulos

Summary: This study investigated the association between MIR155 rs767649 variant and response to anti-TNF therapy in Greek CD and PsO patients. The results showed a significant correlation between the rs767649 variant and therapeutic response in PsO patients, suggesting its potential use as a pharmacogenetic biomarker.

GENES (2023)

Add to Collection

Article Gastroenterology & Hepatology

Transmural healing evaluated by magnetic resonance enterography in paediatric patients with Crohn's disease receiving maintenance treatment with biologics

So Yoon Choi, Eun Sil Kim, Tae Yeon Jeon, Yoo Min Lee, So Mi Lee, Byung-Ho Choe, Yon Ho Choe, Ben Kang

Summary: This study assessed the rate of transmural healing (TH) in pediatric patients with Crohn's disease (CD) after 1 year of treatment with anti-tumor necrosis factor (TNF) agents. TH was found to be a more stringent treatment goal than endoscopic healing (EH), and baseline MaRIA scores were associated with TH.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Anti-TNF Therapies Suppress Adipose Tissue Inflammation in Crohn's Disease

Albert Boronat-Toscano, Diandra Monfort-Ferre, Margarita Menacho, Aleidis Caro, Ramon Bosch, Beatriz Espina, Francisco Algaba-Chueca, Alfonso Saera-Vila, Alicia Moline, Marc Marti, Eloy Espin, Monica Millan, Carolina Serena

Summary: This study found that anti-TNF therapy can restore the morphology of creeping fat in patients with CD, suppress immune cell infiltration, and improve inflammation in adipose tissue.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Review Gastroenterology & Hepatology

Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies

Renske W. M. Pauwels, C. Janneke van der Woude, Daan Nieboer, Ewout W. Steyerberg, Maria J. Casanova, Javier P. Gisbert, Nick A. Kennedy, Charlie W. Lees, Edouard Louis, Tamas Molnar, Kata Szanto, Eduardo Leo, Steven Bots, Robert Downey, Milan Lukas, Wei C. Lin, Aurelien Amiot, Cathy Lu, Xavier Roblin, Klaudia Farkas, Jakob B. Seidelin, Marjolijn Duijvestein, Geert R. D'Haens, Annemarie C. de Vries

Summary: This study validated and updated a prediction model for relapse risk stratification in Crohn's disease (CD) patients after anti-TNF therapy cessation. The updated model, including clinical symptoms at cessation, younger age at diagnosis, no concomitant immunosuppressants, smoking, second-line anti-TNF therapy, upper gastrointestinal tract involvement, adalimumab, age at cessation, C-reactive protein, and longer disease duration, showed a reasonable discriminative ability (C-statistic, 0.59). Adding fecal calprotectin improved the model's discriminative ability (C-statistic, 0.63). Further validation is necessary, but this model may be useful in guiding clinical decisions on anti-TNF therapy cessation in CD patients.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Whole Blood DNA Methylation Changes Are Associated with Anti-TNF Drug Concentration in Patients with Crohn's Disease

Simeng Lin, Eilis Hannon, Mark Reppell, Jeffrey F. Waring, Nizar Smaoui, Valerie Pivorunas, Heath Guay, Neil Chanchlani, Claire Bewshea, Benjamin Y. H. Bai, Nicholas A. Kennedy, James R. Goodhand, Jonathan Mill, Tariq Ahmad, PANTS Consortium

Summary: The study identified epigenetic biomarkers in whole blood at baseline that can predict anti-TNF drug concentrations at week 14, which may help identify patients who could benefit from dose optimization at the beginning of anti-TNF therapy.

JOURNAL OF CROHNS & COLITIS (2023)

Add to Collection

Article Gastroenterology & Hepatology

Effectiveness and safety of tofacitinib for the treatment of ulcerative colitis: A single-arm meta-analysis of observational studies

Fabio Salvatore Macaluso, Marcello Maida, Marco Ventimiglia, Ambrogio Orlando

Summary: Cumulative analysis of real-world studies confirms the good efficacy of TOFA in both induction and maintenance of ulcerative colitis, with a consistent safety profile.

DIGESTIVE AND LIVER DISEASE (2022)

Add to Collection

Article Gastroenterology & Hepatology

Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19

Fabio Salvatore Macaluso, Alessandra Giuliano, Walter Fries, Anna Viola, Alfredo Abbruzzese, Maria Cappello, Enrica Giuffrida, Lucio Carrozza, Antonino Carlo Privitera, Antonio Magnano, Concetta Ferracane, Giuseppe Scalisi, Maria Giovanna Minissale, Emiliano Giangreco, Serena Garufi, Carmelo Bertolami, Ugo Cucinotta, Francesco Graziano, Angelo Casa, Sara Renna, Giulia Teresi, Giulia Rizzuto, Mariella Mannino, Marcello Maida, Ambrogio Orlando

Summary: This retrospective study found that severe inflammatory bowel disease was an independent risk factor for severe COVID-19. Patients with inflammatory bowel disease did not have a higher risk of SARS-CoV-2 infection compared to the general population, and a worse prognosis was not typically associated with immunomodulatory drugs.

INFLAMMATORY BOWEL DISEASES (2023)

Add to Collection

Letter Gastroenterology & Hepatology

Reply to Comment on: Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease

Fabio Salvatore Macaluso, Ambrogio Orlando

DIGESTIVE AND LIVER DISEASE (2023)

Add to Collection

Article Gastroenterology & Hepatology

Re duce d humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study

Fabio Salvatore Macaluso, Mariabeatrice Principi, Federica Facciotti, Antonella Contaldo, Alessia Todeschini, Simone Saibeni, Cristina Bezzio, Fabiana Castiglione, Olga Maria Nardone, Rocco Spagnuolo, Massimo Claudio Fantini, Gaia Riguccio, Flavio Caprioli, Chiara Vigano, Carla Felice, Gionata Fiorino, Carmen Correale, Giorgia Bodini, Monica Milla, Giulia Scardino, Marta Vernero, Federico Desideri, Mariella Mannino, Giuseppe Rizzo, Ambrogio Orlando

Summary: The study investigated the humoral response to COVID-19 vaccines in patients with inflammatory bowel disease (IBD) treated with immunomodulatory or biological drugs. The majority of IBD patients showed seropositivity after COVID-19 vaccination, but the magnitude of the humoral response was significantly lower compared to healthy controls. These findings suggest that the lower response is mostly unrelated to the use of immune-modifying treatments.

DIGESTIVE AND LIVER DISEASE (2023)

Add to Collection

Article Gastroenterology & Hepatology

The effectiveness of ustekinumab and vedolizumab as third-line biologic therapy in patients with Crohn?s disease

Fabio Salvatore Macaluso, Mauro Grova, Marica Saladino, Maria Cappello, Maria Giulia Demarzo, Antonino Carlo Privitera, Emiliano Giangreco, Serena Garufi, Sara Renna, Angelo Casa, Marco Ventimiglia, Walter Fries, Ambrogio Orlando

Summary: This study assessed the effectiveness of Ustekinumab (UST) and Vedolizumab (VDZ) as third-line biologic therapy in patients with Crohn's disease (CD) and found that both treatments were highly effective.

DIGESTIVE AND LIVER DISEASE (2023)

Add to Collection

Letter Gastroenterology & Hepatology

Switching from SB2 to PF-06438179/GP1111 and back in inflammatory bowel disease: ?The Superswitchers?

Fabio Salvatore Macaluso, Angelo Casa, Sara Renna, Mauro Grova, Mariella Mannino, Ambrogio Orlando

DIGESTIVE AND LIVER DISEASE (2023)

Add to Collection

Editorial Material Gastroenterology & Hepatology

Editorial: adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease-time for universal recommendation?

Fabio Salvatore Macaluso, Ambrogio Orlando

Summary: This article is linked to Caldera et al papers.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Add to Collection

Letter Gastroenterology & Hepatology

Author's Reply: Use of biologics for the management of Crohn's disease

Stefanos Bonovas, Fabio Salvatore Macaluso, Daniele Piovani, Claudio Papi, Ambrogio Orlando, Alessandro Armuzzi

DIGESTIVE AND LIVER DISEASE (2023)

Add to Collection

Article Gastroenterology & Hepatology

Use of biologics for the management of Crohn?s disease: IG-IBD clinical guidelines based on the GRADE methodology

Fabio Salvatore Macaluso, Claudio Papi, Ambrogio Orlando, Stefano Festa, Daniela Pugliese, Stefanos Bonovas, Claudia Pansieri, Daniele Piovani, Gionata Fiorino, Massimo Claudio Fantini, Flavio Caprioli, Marco Daperno, Alessandro Armuzzi

Summary: A cure for Crohn's disease is currently unavailable, so lifelong management is necessary. Different biological drugs have been approved, including monoclonal antibodies targeting inflammatory pathways and adipose-derived stromal cells for perianal fistula. Italian guidelines on the use of biologics for managing CD have been issued, providing recommendations for different clinical settings. The recommendations are based on evidence from real world studies.

DIGESTIVE AND LIVER DISEASE (2023)

Add to Collection

Article Gastroenterology & Hepatology

Effectiveness and Safety of Vedolizumab in Inflammatory Bowel Disease: A Comprehensive Meta-analysis of Observational Studies

Fabio Salvatore Macaluso, Marco Ventimiglia, Ambrogio Orlando

Summary: This study comprehensively summarized the effectiveness and safety of vedolizumab in patients with Crohn's disease (CD) and ulcerative colitis (UC) based on pooled data from observational studies. The results showed that vedolizumab had high rates of clinical remission in both induction and maintenance phases for CD and UC patients, with a low incidence rate of adverse events.

JOURNAL OF CROHNS & COLITIS (2023)

Add to Collection

Article Gastroenterology & Hepatology

Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's disease

Fabio Salvatore Macaluso, Mauro Grova, Filippo Mocciaro, Roberto Di Mitri, Antonino Carlo Privitera, Maria Emanuela Distefano, Alessandro Vitello, Salvatore Camilleri, Concetta Ferracane, Dario Pluchino, Nunzio Belluardo, Emiliano Giangreco, Walter Fries, Anna Viola, Maria Cappello, Livia D'Amato, Carmelo Bertolami, Marco Ventimiglia, Sara Renna, Angelo Casa, Elvira D'Antonio, Simona De Vivo, Ambrogio Orlando

Summary: According to the study, ustekinumab shows promising results in treating postoperative recurrence of Crohn's disease. This highlights the importance of ustekinumab as a treatment option for CD patients.

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2023)

Add to Collection

Article Gastroenterology & Hepatology

Lack of Seroconversion Following COVID-19 Vaccination Is an Independent Risk Factor for SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: Data from ESCAPE-IBD, an IG-IBD Study

Fabio Salvatore Macaluso, Mariabeatrice Principi, Federica Facciotti, Antonella Contaldo, Alessia Todeschini, Simone Saibeni, Cristina Bezzio, Fabiana Castiglione, Olga Maria Nardone, Rocco Spagnuolo, Massimo Claudio Fantini, Gaia Riguccio, Simone Conforti, Flavio Caprioli, Chiara Vigano, Carla Felice, Gionata Fiorino, Carmen Correale, Giorgia Bodini, Monica Milla, Giulia Scardino, Marta Vernero, Federico Desideri, Fabrizio Bossa, Maria Guerra, Marco Ventimiglia, Angelo Casa, Giuseppe Rizzo, Ambrogio Orlando

Summary: This prospective study has shown that a lack of seroconversion after receiving two doses of COVID-19 vaccines is a significant predictor of SARS-CoV-2 infection. Additionally, the treatments for inflammatory bowel disease (IBD) do not increase the risk of SARS-CoV-2 infection.

INFLAMMATORY BOWEL DISEASES (2023)

Add to Collection

Meeting Abstract Gastroenterology & Hepatology

Sarcopenia is a poor prognostic factor for endoscopic outcomes in patients with Crohn's disease

M. Grova, F. Crispino, M. Maida, A. Vitello, L. Tese, G. Rizzuto, A. Casa, S. Renna, F. S. Macaluso, A. Orlando

JOURNAL OF CROHNS & COLITIS (2022)

Add to Collection

Meeting Abstract Gastroenterology & Hepatology

Sarcopenia is a poor prognostic factor for endoscopic outcomes in patients with Crohn's disease

M. Grova, F. Crispino, M. Maida, A. Vitello, L. Tese, G. Rizzuto, A. Casa, S. Renna, F. S. Macaluso, A. Orlando

JOURNAL OF CROHNS & COLITIS (2022)

Add to Collection

Letter Medicine, General & Internal

Ozanimod for Ulcerative Colitis

Fabio S. Macaluso, Ambrogio Orlando

Summary: The phase 3 trial of ozanimod for induction and maintenance therapy in patients with moderately to severely active ulcerative colitis raised concerns about the requirement for stable doses of oral aminosalicylates or glucocorticoids for eligible patients. Subsequent evaluation of treatment efficacy and safety measures should consider this aspect.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.